P3I
REGN icon

Progeny 3 Inc’s Regeneron Pharmaceuticals REGN Stock Holding History

Progeny 3 Inc’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-2,082
Closed -$1.02M – 32
2020
Q1 		$1.02M Buy
+2,082
New +$859K 0.43% 24

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Progeny 3 Inc's REGN Position: Q2 2020 in Review

Progeny 3 Inc sold out of Regeneron Pharmaceuticals (REGN) in Q2 2020, closing a stake of 2,082 shares — an estimated $1.02M sold.

Progeny 3 Inc first reported a position in REGN in Q1 2020 and held it in 1 quarter. The position peaked at $1.02M in Q1 2020. 932 funds tracked by Wall St. Rank hold REGN as of Q2 2020.

  • Progeny 3 Inc reported no remaining Regeneron Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Progeny 3 Inc sold 2,082 Regeneron Pharmaceuticals shares in Q2 2020, an estimated $1.02M.
  • Progeny 3 Inc first reported a position in Regeneron Pharmaceuticals in Q1 2020 and held it in 1 quarter.
  • Progeny 3 Inc's Regeneron Pharmaceuticals position peaked at $1.02M in Q1 2020.
  • 932 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2020.

Based on Progeny 3 Inc's 13F filing for Q2 2020, filed 14 Aug 2020.